Oncology
Gastric/gastroesophageal Junction Cancer
0
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Gastric/Gastroesophageal Junction Cancer is an early-stage landscape with 0 programs across 2 companies. The most active players are Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Five Prime Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Completed2 · 29%
Recruiting2 · 29%
Terminated1 · 14%
Not yet recruiting1 · 14%
Unknown status1 · 14%
Clinical Trials
Trial Activity
7 trials
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
Recruiting·—·Phase 2·NCT05033392·62 enrolled
TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05447234·50 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)